Non-calcium-containing phosphate binders: comparing efficacy, safety, and other clinical effects
JM Frazão, T Adragão - Nephron Clinical Practice, 2012 - karger.com
Phosphate-binder therapy for hyperphosphataemia is key to the treatment of patients with
chronic kidney disease (CKD)-mineral and bone disorder (MBD). Calcium-free phosphate …
chronic kidney disease (CKD)-mineral and bone disorder (MBD). Calcium-free phosphate …
The efficacy of cinacalcet combined with conventional therapy on bone and mineral metabolism in dialysis patients with secondary hyperparathyroidism: a meta …
D Li, L Shao, H Zhou, W Jiang, W Zhang, Y Xu - Endocrine, 2013 - Springer
Cinacalcet, the first calcimimetic to be approved for the treatment of secondary
hyperparathyroidism (SHPT) in the chronic kidney disease patients, offers a novel …
hyperparathyroidism (SHPT) in the chronic kidney disease patients, offers a novel …
Paricalcitol reduces basal and lipopolysaccharide-induced (LPS) TNF-α and IL-8 production by human peripheral blood mononuclear cells
T Eleftheriadis, G Antoniadi, V Liakopoulos… - … Urology and Nephrology, 2010 - Springer
Introduction Vitamin D and its analogues proved to exert immunomodulatory effects.
Paricalcitol is a vitamin D analogue that is safe. It has been used for years in the treatment of …
Paricalcitol is a vitamin D analogue that is safe. It has been used for years in the treatment of …
Effects of systematic nursing instruction on a low‐phosphorus diet, serum phosphorus level and pruritus of patients on haemodialysis
TY Cheng, DC Tarng, YM Liao… - Journal of clinical …, 2017 - Wiley Online Library
Aims and objectives To investigate the effectiveness of systematic nursing instruction on a
low‐phosphorus diet, serum phosphorus level and pruritus of haemodialysis patients …
low‐phosphorus diet, serum phosphorus level and pruritus of haemodialysis patients …
Bone mineral density in patients on maintenance dialysis
Disorders of bone and mineral metabolism affect almost all patients with advanced chronic
kidney disease (CKD). High prevalence of decreased bone mineral density has been …
kidney disease (CKD). High prevalence of decreased bone mineral density has been …
Loss via peritoneal fluid as a factor for low 25 (OH) D3 level in peritoneal dialysis patients
Background/aims In patients with end-stage renal disease (ESRD), the 25-hydroxyvitamin
D3 (25 (OH) D3) level is known to be lower compared to that of the normal population. In the …
D3 (25 (OH) D3) level is known to be lower compared to that of the normal population. In the …
Plasma levels of fibroblast growth factor-23 and mineral metabolism in diabetic and non-diabetic patients on chronic hemodialysis
F Kojima, K Uchida, T Ogawa, Y Tanaka… - International urology and …, 2008 - Springer
Objective Fibroblast growth factor (FGF) 23 is a circulating factor that regulates phosphate
(P) metabolism. Since higher P levels are associated with vascular calcification, we …
(P) metabolism. Since higher P levels are associated with vascular calcification, we …
Direct comparison of regulators of calcification between bone and vessels in humans
N Schweighofer, A Aigelsreiter, O Trummer… - Bone, 2016 - Elsevier
Calcification is not only physiologically present in bone but is a main pathophysiological
process in vasculature, favouring cardiovascular diseases. Our aim was to investigate …
process in vasculature, favouring cardiovascular diseases. Our aim was to investigate …
Evaluation of Morbidity and Mortality Data Related to Cardiovascular Calcification from Calcium‐Containing Phosphate Binder Use in Patients Undergoing …
MA Mason, BM Shepler - Pharmacotherapy: The Journal of …, 2010 - Wiley Online Library
Cardiovascular disease is the leading cause of death among patients with stage 5 chronic
kidney disease. Several mechanisms are thought to contribute to vascular calcification and …
kidney disease. Several mechanisms are thought to contribute to vascular calcification and …
[PDF][PDF] CKD 患者高磷血症治疗进展---新型磷结合剂的应用
袁群生， 郑法雷 - 中国血液净化, 2015 - cjbp.org.cn
对慢性肾脏病(chronic kidney disease, CKD) 患者而言, 当磷潴留超过一定水平时,
即成为尿毒症毒素之一. 目前, 磷的清除方法有了很大进展, 某些新型磷结合剂相继得到研究开发 …
即成为尿毒症毒素之一. 目前, 磷的清除方法有了很大进展, 某些新型磷结合剂相继得到研究开发 …